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Screening of a Library of Recombinant Schistosoma 
mansoni Proteins With Sera From Murine and Human 
Controlled Infections Identiies Early Serological Markers
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Jacqueline J. Janse,2 Shona Wilson,3 Matthew Berriman,1 Meta Roestenberg,2 and Gavin J. Wright1
1Wellcome Sanger Institute, Cambridge, United Kingdom, 2Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands, 3Department of Pathology, University of 
Cambridge, Cambridge, United Kingdom
Background. Schistosomiasis is a major global health problem caused by blood-dwelling parasitic worms, which is currently 
tackled primarily by mass administration of the drug praziquantel. Appropriate drug treatment strategies are informed by diagnos-
tics that establish the prevalence and intensity of infection, which, in regions of low transmission, should be highly sensitive. 
Methods. To identify sensitive new serological markers of Schistosoma mansoni infections, we have compiled a recombinant 
protein library of parasite cell-surface and secreted proteins expressed in mammalian cells. 
Results. Together with a time series of sera samples from volunteers experimentally infected with a deined number of male 
parasites, we probed this protein library to identify several markers that can detect primary infections with as low as 10 parasites and 
as early as 5 weeks postinfection.
Conclusions. hese new markers could be further explored as valuable tools to detect ongoing and previous S mansoni infec-
tions, including in endemic regions where transmission is low.
Keywords.  antibodies; Schistosoma mansoni; schistosomiasis; serology.
Schistosomiasis is a neglected tropical disease affecting more 
than 200 million people in 52 countries and is one of the world’s 
major health problems causing 200 000 deaths per year. In 2015, 
the impact of the disease was estimated at 3.5 million disability-
adjusted life years, putting a huge socioeconomic burden on 
many low- and middle-income countries [1]. In humans, schis-
tosomiasis is caused by 5 species of platyhelminth parasites 
belonging to the genus Schistosoma. Their geographical distri-
bution is restricted by the presence of species-specific freshwater 
snails that act as intermediate hosts, with Schistosoma mansoni 
having the most widespread distribution, encompassing both 
Africa and South America [2]. Infected snails shed cercariae, 
a free-swimming larva, which penetrates human skin to in-
itiate infection. Parasite maturation within its host takes sev-
eral weeks: cercarial heads first remodel their surface to form 
schistosomula [3], which migrate through the dermis for several 
days before entering the host bloodstream. Eventually, young 
adult male and female S mansoni worms pair up in the liver 
before moving to the mesenteric blood vessels, where each pair 
can release over 300 eggs per day from 5 weeks postinfection 
[4]. The symptoms of schistosomiasis are caused by progressive 
accumulation of eggs within host tissues, eliciting host-derived 
immune responses that can eventually lead to liver fibrosis, 
portal hypertension, and, if left untreated, death [5]. In the 
absence of a licenced vaccine, treatment relies on the use of a 
single drug, praziquantel.
he exact prevalence of schistosomiasis worldwide may 
be underestimated due to limitations of routine methods of 
detection [6]. Diagnosis of S mansoni infections and subse-
quent decisions on mass drug administration mainly rely on 
observing parasite eggs in patients’ stools with the Kato-Katz 
test. Although this method can detect current infections, it is 
not sensitive enough to diagnose low levels of infection present 
in low-endemicity areas or in recently treated populations 
[7]. In these instances, detection of parasite antigens such as 
the circulating cathodic antigen or circulating anodic antigen 
(CAA) in patients’ sera or urine by sensitive ield-applicable or 
laboratory-based assays is highly useful [8–10]. In areas where 
elimination has been achieved, the detection of antiparasite 
serum antibodies could support epidemiological surveillance 
that informs of any risk of resurgence. Host antibody responses 
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to S mansoni parasites is oten measured against whole parasite 
extracts such as soluble egg antigens (SEA) or soluble worm an-
tigen preparation (SWAP), which are not molecularly deined 
and can lead to cross-reactivity with other helminth species. 
Although a diagnostic test based on a recombinant protein 
could mitigate these problems, only very few have been used to 
test patient antibody responses to Schistosoma infections [11]. 
he development of new, more sensitive diagnostic tools would 
therefore help to improve the detection and early treatment of 
schistosomiasis.
Extracellular antigens released by or displayed at the surface 
of the parasite at the initial stage of infection [3] can be valu-
able early immunodiagnostic markers because they are directly 
exposed to the host humoral system. he identiication of such 
antigens has been aided by the sequencing and annotation of 
the S mansoni genome [12], and several proteomics [13–20], 
transcriptomics, and in silico analyses [21–23] have identiied 
genes expressed by the schistosomula and adult worm. Despite 
their value, extracellular proteins pose challenges for recom-
binant expression because they contain structurally important 
posttranslational modiications such as glycosylation and espe-
cially disulphide bonds required to produce informative anti-
body epitopes. To address this, we have previously developed 
protein expression approaches in mammalian cells to compile 
large panels of parasite recombinant ectodomains that retain 
their binding activity and immunogenicity [24], enabling the 
identiication of host-parasite receptor-ligand interactions and 
humoral markers of protection against malaria [25].
To identify new markers for S mansoni infections, we created 
a panel of 115 recombinant proteins representing secreted and 
membrane-tethered S mansoni proteins mostly enriched at the 
schistosomula stage. Using human and mouse sera from exper-
imentally controlled S mansoni infections, we determined the 
kinetics of humoral responses to this panel of antigens in the 
context of primary infections and identiied several early sero-
logical markers.
MATERIAL AND METHODS
Identification of Schistosoma mansoni Cell-Surface and Secreted Proteins
Genes encoding cell-surface and secreted proteins from 
cercarial and adult S mansoni were identified using published 
proteomic and transcriptional data [13–16, 19–21]. To fur-
ther enrich for genes transcribed at the schistosomula stage, 
we identified 1302 transcripts upregulated at 48 versus 3 hours 
posttransformation [26] using EdgeR [27] as well as the 1000 
most abundant transcripts at 48 hours as assessed by reads per 
kilobase mapped, resulting in 1977 unique genes, 274 of which 
encoded secreted and cell-surface proteins identified using 
signal peptide and transmembrane domain prediction soft-
ware [28, 29]. All RNA-seq data are available in the European 
Nucleotide Archive (ENA) under study PRJEB3190 and run 
accession numbers ERR411525, ERR411535, and ERR411541 
for the 3-hour time point and ERR411522, ERR411527, and 
ERR411538 for the 48-hour time point. Ninety-four mitochon-
drial, endoplasmic reticulum, or multipass proteins, which 
are difficult to express as a contiguous ectodomain, were sub-
sequently excluded, leaving a short list of 180 proteins. Gene 
structures were manually refined by mapping transcriptome 
data to the genome sequence, and genes spanning gaps in the 
genome sequence or with ambiguity in structure were removed, 
resulting in a final list of 115 candidates numbered in Table 1.
Recombinant Protein Expression Using a Mammalian Expression System
The entire ectodomain of membrane-anchored proteins was 
selected, their signal peptide removed using predictions from 
SignalP v3.0, and the corresponding cDNAs were made by gene 
synthesis after codon-optimization for expression in human 
cells (GeneArt; Invitrogen). The ectodomains were flanked 
by unique NotI and AscI restriction sites and subcloned into 
an expression plasmid containing the mouse V
K
7–33 signal 
peptide [24], and a C-terminal tag containing rat Cd4d3  +  4 
domain, a BirA monobiotinylation sequence, and 6-His tag 
(Addgene plasmid no. 50 803) [30]. All expression constructs 
are available at www.addgene.org (plasmids nos. 120 590 to 
120 704). Plasmids were transiently cotransfected with BirA 
in HEK293-E or -6E cells, supernatants were collected, and 
recombinant proteins were detected by Western blotting with 
0.02  µg/mL streptavidin-HRP (Jackson ImmunoResearch) as 
previously described [24]. When proteins showed signs of pro-
teolytic cleavages, transfections were repeated in the presence of 
a protease inhibitor cocktail (Sigma).
Human Samples From Endemic Regions and Experimentally Controlled 
Infections
To initially characterize the immunoreactivity of the proteins, 
we used plasma pools from 10 nonexposed European controls 
and 10 Ugandan adults from a cohort living in a high transmis-
sion area [31, 32]. Individuals were selected from those who had 
a soluble worm antigen immunoglobulin (Ig)G1 response in the 
upper third for the cohort with a median egg count of 876 eggs 
per gram (epg) (interquartile range, 345–1967 epg). All patient 
samples were collected in accordance with the Uganda National 
Council for Science and Technology and the Cambridge Local 
Research Ethics Committee. Sera or plasma from volunteers 
experimentally infected percutaneously with 10–30 male cer-
cariae were collected weekly in accordance with the LUMC 
Institutional Medical Ethical Research Committee (P16.111), as 
previously described [33]. All volunteers were treated with pra-
ziquantel 12 weeks after infection.
Sera From Experimental Mouse Infections
The life cycle of the NMRI (Puerto Rican) strain of S mansoni 
was maintained by routine infections of mice and susceptible 
Biomphalaria glabrata snails under the UK Home Office Project 
Licence nos. P77E8A062 and PD3DA8D1F; all protocols were 
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Table 1. Details of 115 Cell-Surface and Secreted Proteins From Schistosoma mansonia 
Number Accession No. Name Boundaries MM Domain/Protein Similarity Level Ref.
 Cell Surface
1 Smp_195190 Sm13 E18-T80 37  High [17]
2 Smp_081920 SmLy6I (Cd59.5) L26-T104 45  Medium [17]
3 Smp_166340 SmLy6F (Cd59.4) L26-S98 47  Medium [17]
4 Smp_017730 Sm200 D20-S1662 257  Medium [14]
5 Smp_127820  V18-S760 132  Medium [14]
6 Smp_194920  D17-T592 98 T-cell immunomodulatory protein Low [14]
7 Smp_011680  L30-P348 87 Cd36-like class B scavenger receptor Low  
8 Smp_054070  D31-S210 71 TM2 domain-containing protein 3 High  
9 Smp_073400  R25-T214 78 LAMP-like protein Medium  
10 Smp_105220 SmLyB (Cd59.2) I20-P99 42  High [15]
11 Smp_019350 SmLy6A (Cd59.1) H28-T102 38  High [15]
12 Smp_021220  E24-S119 53  High  
13 Smp_031880  R18-S240 58 Ig domain-containing protein, basigin-related High  
14 Smp_009830  D20-S149 51 Translocon-associated protein subunit beta Low  
15 Smp_032520  Y19-R200 74 LAMP-like protein High  
16 Smp_074000  I19-I232 56  Low  
17 Smp_102480  N29-D66 37  High  
18 Smp_124000 MEG-14 T27-D110 38  High  
19 Smp_156270  S23-P144 47 Post-GPI attachment to protein factor Low  
20 Smp_174580  S17-T275 59 Vesicular integral membrane protein High  
21 Smp_176020 MEG-11 D23-P55 34  High  
22 Smp_048380  L20-S283 73  Medium  
23 Smp_060570  Y21-S428 85  Low  
24 Smp_075280  V19-T222 77 LAMP-like protein High  
25 Smp_129840  G25-S1161 206  Medium  
26 Smp_133270  E34-T759 120 Sel1-like protein -  
27 Smp_145420  H30-I1733 282 Plexin A3 -  
28 Smp_149740  F26-T560 130 Alzheimer disease beta-amyloid related Medium  
29 Smp_155810  L29-T1100 184 Protocadherin 11 Medium  
30 Smp_162520  N20-P1070 162 Protocadherin fat4 Low  
31 Smp_164760  S22-P1160 184 IgSF Low  
32 Smp_166300  N27-I356 94  High  
33 Smp_168240  Q25-T263 68  High  
34 Smp_171460  L19-S841 161 IgSF Medium  
35 Smp_176540  V31-T956 146 Protocadherin 18 Medium  
36 Smp_157070  I19-P397 83 EGF-domain-containing protein Low  
37 Smp_165440  Q25-P363 74 Netrin receptor unc5 Low  
38 Smp_136690  N26-T674 118 Acetylcholinesterase Medium [17]
39 Smp_061970  F21-P518 95 GPI ethanolamine phosphate transferase 2 -  
40 Smp_153390 SmNNP5 S19-S428 95  Medium [14]
41 Smp_072190 SmLy6D (Sm29) V27-T168 57  High [14]
42 Smp_064430  A22-S155 53  Medium [19]
 Secreted Adhesion/Growth Factor/Metabolite Binding
43 Smp_194840  E18-I146 47 NPC-like cholesterol-binding protein High [50]
44 Smp_194910  N22-I180 51 Saposin B domain-containing protein Medium [20]
45 Smp_063530  E26-R193 49 Apoferritin Medium [50]
46 Smp_141680  I33-A659 110 Fasciclin domain-containing protein High [14]
47 Smp_043650  Q23-L81 37 Prohormone npp-28 Low  
48 Smp_170550  N27-Y928 164 Granulin Medium  
49 Smp_035040  N24-L241 63 IgSF Low  
50 Smp_052660  I22-R488 97 Matabotropic glutamate receptor -  
51 Smp_128590  K21-S260 69 Laminin gamma3 Low  
52 Smp_135210  I21-Q1584 220 EGF-domain-containing protein Low  
53 Smp_136320  H21-K154 48 GSK3beta-interacting protein Low  
54 Smp_144130  L26-V553 118 Septate junction protein Low  
55 Smp_154760  Q30-M2155 298 EGF-domain-containing protein Low  
56 Smp_171780  Q19-K260 61 SPARC High  
57 Smp_178740  Q31-V533 97 Tesmin-related protein Low  
58 Smp_180600  S22-S292 72 IGF-binding protein High  
59 Smp_181220  N18-I173 50 C1q-binding protein Medium  
60 Smp_211020  L32-Y703 122 Discoidin domain-containing protein -  
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Number Accession No. Name Boundaries MM Domain/Protein Similarity Level Ref.
61 Smp_016490  E21-Q194 53 SaposinB domain-containing protein Medium  
62 Smp_130100  F20-I128 45 Saposin domain-containing protein Low [20]
63 Smp_105420  I19-S196 53 Saposin domain-containing protein High  
64 Smp_105450  Y19-C126 58 Saposin domain-containing protein Medium [50]
65 Smp_202610  V19-T135 46 Saposin domain-containing protein Medium  
 Secreted Proteases
66 Smp_090100  E24-Q582 98 Invadolysin Low [16]
67 Smp_067060  H18-N340 73 Cathepsin B1, isotype2 High [50]
68 Smp_103610 SmCB1 (Sm31) H18-N340 73 Cathepsin B1, isotype1 Low [50]
69 Smp_019030  D21-L455 91 Cathepsin C/Dipeptylpeptidase 1 Low [50]
70 Smp_002600  L17-G498 111 Lysosomal Pro X carboxypeptidase Medium [50]
71 Smp_071610  I24-L472 99 Dipeptidyl-peptidase II Medium [50]
72 Smp_089670  S19-N2127 409 Alpha-2 macroglobulin Medium [15]
73 Smp_112090 SmCE2a.3 F19-I263 56 Cercarial elastase 2a - [16]
74 Smp_119130 SmCE1a.2 W25-I263 55 Cercarial elastase 1a - [16]
75 Smp_002150 SmSP2 S25-F501 97 Trypsin-like serine protease Low  
76 Smp_141610 SmCB2 N23-N347 72 Cathepsin B Medium  
77 Smp_147730 SmKI-1 Y21-K146 47 Kunitz-type protease inhibitor Medium  
78 Smp_034420 Sm12.8 N20-S148 56 Cystatin Medium  
79 Smp_075800  Q20-G429 83 Hemoglobinase Low  
80 Smp_210500 SmCL3 D17-V370 75 Cathepsin L3 Medium  
81 Smp_132480  E16-S393 79 Subfamily A1A unassigned peptidase Low  
82 Smp_166280  C20-L337 79 Glutaminyl cyclase Medium  
83 Smp_187 140  K21-F342 74 Cathepsin L Low  
84 Smp_006510 SmCE2a.2 W25-I263 53 Cercarial elastase 2a - [19]
85 Smp_090110  E24-I591 103 Invadolysin - [19]
 Other Secreted Enzymes
86 Smp_145920  Y30-F340 71 Protein tyrosine sulfotransferease Low  
87 Smp_040790  E24-E213 54 Peptidyl prolyl cis-trans isomerase B Medium  
88 Smp_008320  D18-D325 72 Pap-inositol-1,4-phosphatase Low  
89 Smp_021730  G30-D220 52 Cytochrome c oxydase subunit Vb Low  
90 Smp_078800  E25-S192 49 DnaJ subfamily B Low  
91 Smp_007450  R22-G160 48 Heat-shock 67b2 Medium  
92 Smp_026930  T51-V442 85 Acetylglucosaminyltransferase Medium  
93 Smp_059910  D28-Q274 70 Ser-Thr protein phosphatase -  
94 Smp_089240  K43-Y498 93 Acetylglucosaminyltransferase -  
95 Smp_134800  K20-T1590 242 Tyr protein kinase Low  
96 Smp_018760  N25-L991 152 Alpha glucosidase Low [19]
Secreted VALs/MEGs
97 Smp_194860 Sm8.7 E20-E92 39  Medium [17]
98 Smp_138080 MEG-3.1 A21-S146 50  High [17]
99 Smp_194830 SmKK7 K21-D79 37  High [16]
100 Smp_001890 VAL18 K27-Y194 55  Low [16]
101 Smp_002070 VAL4 K22-E181 57  Low [16]
102 Smp_138060 MEG-3.3 A21-G151 46  High  
103 Smp_180620 MEG-17 N17-R65 41  High  
104 Smp_123540 VAL12 I22-L24 57  Low  
105 Smp_123550 VAL8 Q24-K261 66  Medium  
 Putative Secreted Proteins
106 Smp_181070  K25-Q114 43  Low  
107 Smp_004710  M26-S127 42  High  
108 Smp_061310  Y20-E140 65  Low  
109 Smp_005060  E17-I146 45  -  
110 Smp_141500  N27-L121 56  High  
111 Smp_006060  P35-P380 92  High  
112 Smp_063330  K24-F182 48  High  
113 Smp_096 790  T21-E94 38  Medium  
114 Smp_201730  E24-R92 38  Medium  
115 Smp_019000  D28-D236 53  Medium [19]
Abbreviations: EGF, epidermal growth factor; GPI, glycosylphosphatidylinositol; GSK3beta, glycogen synthase kinase 3 beta; Ig, immunoglobulin; IGF, insulin-like growth factor; IgSF, Ig superfamily; LAMP, lysosome-
associated membrane glycoprotein; MEGs, micro-exon genes; MM, molecular mass; NPC, Niemann-Pick C; NPP, ectonucleotide pyrophosphatase/phosphodiesterase; Ref., reference; SPARC, secreted protein acidic 
and rich in cysteine; VAL, venom allergen-like.
aFor each protein, we show the accession number, alternative name, boundaries of the extracellular domain expressed in mammalian cells, expected MM in kilodaltons, domain similarities, and level of expression as deter-
mined by enzyme-linked immunosorbent assay (ELISA). References to previous proteomics studies where this protein was identiied are provided where available. The expected MM of each protein was calculated by adding 
3 kDa per predicted glycosylation site (the average mass of a N-linked glycan) to the expected mass of the protein. Levels of expression were determined from each ELISA proile as detailed under Material and Methods. 
Table 1. Continued
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approved by the local Animal Welfare and Ethical Review Body 
(AWERB). Seven-week-old BALB/c female mice were infected 
percutaneously by tail immersion in water containing 200 cer-
cariae for 40 minutes under general anaesthesia or by injection 
of 350 cercariae intraperitoneally. Blood samples were collected 
at 8, 21, and 42 days postinfection.
Enzyme-Linked Immunosorbent Assays 
Protein expression was quantified by enzyme-linked immu-
nosorbent assay (ELISA) as previously described [24]. Briefly, 
serial dilutions of biotinylated proteins were captured on 
streptavidin-coated microtitre plates and detected by mouse 
antirat Cd4 OX68 antibody (AbD Serotec), followed by an 
alkaline-phosphatase-conjugated antimouse secondary an-
tibody (Sigma), and proteins were classified into high (typi-
cally >5  µg/mL transfection supernatant), medium (between 
1 and 5 µg/mL), and low (<1 µg/mL) levels of expression. To 
determine the presence of heat-labile epitopes, biotinylated 
proteins were captured on streptavidin-coated plates either 
untreated or after heat treatment for 10 minutes at 80°C be-
fore incubation with sera at 1:1000 dilution in HBST/2% bo-
vine serum albumin (HBST/2%BSA). Statistical analysis was 
performed in GraphPad Prism using the Holm-Sidak method 
for multiple t tests. Sera from human volunteers or experi-
mentally infected mice were diluted 1:250 or 1:1000, respec-
tively, in HBST/2%BSA; binding was detected with horseradish 
peroxidase-conjugated antihuman or antimouse secondary 
antibodies (Sigma), respectively, recognizing IgA, IgM, and 
IgG. For each individual, the optical density (OD) value of the 
preinfection samples was reference-subtracted from the OD 
readings at all subsequent time points. The OD values for each 
protein were compared with that of the rat Cd4d3 + 4 tag used 
as a negative control, and seropositivity was defined as OD
protein
 
> OD
control
 + 3SD
control
.
RESULTS
Selection and Expression of a Panel of 115 Secreted and Cell-Surface 
Proteins From Schistosoma mansoni
To compile a library of recombinant S mansoni proteins, we used 
published proteomics data to identify 40 proteins predicted to 
be located on the surface or secreted by the parasite (Table 1). 
Because membrane and secreted proteins of the schistosomula 
stage were underrepresented in proteomics datasets, we sup-
plemented our library using transcriptomics data. To identify 
genes transcribed early after infection, we selected 1302 tran-
scripts enriched at 48 versus 3 hours postinfection and the 
1000 most abundant transcripts in the 48-hour schistosomula. 
Proteins likely to be secreted or membrane-anchored were iden-
tified, resulting in a list of 274 genes. Of those, mitochondrial, 
endoplasmic reticulum proteins, and those with incomplete 
open reading frames were excluded so that 75 new candidates 
were added for a total of 115 genes (Table  1). One third en-
coded single-pass transmembrane or GPI-anchored proteins, 
and the remaining secreted proteins were divided into 5 broad 
categories (Table 1). Proteins were expressed in HEK293 cells, 
quantified by ELISA, and their integrity was determined by 
Western blotting (Table  1, Figure  1). Most proteins were de-
tected at their expected size including the very large proteins 
Sm200 (257  kDa, protein 4)  and α 
2
-macroglobulin (409  kDa, 
198
kDa
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Figure 1. A library of 115 recombinant cell-surface and secreted proteins from Schistosoma mansoni expressed as secreted enzymatically monobiotinylated recombinant 
proteins in HEK293 cells. Supernatants were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions, blotted, and 
detected with streptavidin-conjugated horseradish peroxidase. Approximately one third of the protein library consists of membrane-tethered surface proteins, whereas the 
remainder of the library corresponds to secreted proteins as indicated. Their predicted molecular mass is indicated by a red line. Three proteins (52, 57, 86) migrated faster 
than expected; 6 proteins (42, 68, 80, 89, 91, 102) exhibited evidence of partial processing; 13 proteins were not detected by Western blotting.
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protein 72) (Figure 1), and only 12 (10%) could not be detected 
(Table 1, Figure 1). This library of recombinant S mansoni sur-
face and secreted proteins represents a valuable resource for im-
munological and functional studies.
Schistosoma mansoni Recombinant Proteins Expressed in Mammalian 
Cells Contain Heat-Labile Conformational Epitopes
Many antibodies elicited in the context of a natural in-
fection recognize conformational epitopes present on 
the native protein. To determine the fraction of proteins 
containing conformational epitopes, we compared the 
immunoreactivity of pooled plasma from chronically ex-
posed individuals to untreated and heat-treated proteins. 
All except proteins 18 and 57 were seropositive, and 66 of 
the expressed proteins (64%) were highly immunoreactive 
(A
280 
>  0.3) (Figure  2). The majority of proteins showed 
moderate to strong loss of immunoreactivity after heat 
treatment; only 16 of the highly reactive proteins showed 
no statistically significant loss of reactivity, suggesting that 
they were either natively unstructured, misfolded, or con-
tained heat-stable domains (Figure 2). Overall, the recom-
binant proteins were therefore immunoreactive to plasma 
from individuals living in high-endemicity areas and con-
tained heat-labile epitopes.
Serological Profiles of Human Experimental Schistosoma mansoni 
Infections
The recent establishment of controlled human S mansoni infec-
tions [33, 34] provided a unique opportunity to identify early 
serological markers of infection and the kinetics of the host 
antibody response in an experimentally controlled setting. We 
initially tested plasma taken at 4 weekly intervals from 3 vo-
lunteers, each infected with 30 male cercariae, against our 103 
expressed S mansoni proteins. As expected, compared with 
high-endemicity plasma, fewer antigens were immunoreactive, 
but several were immunopositive in all participants, and the 
number of positive antigens increased over time (Figure  3). 
Five antigens (44, 63, 65, 67, and 68) showed consistently strong 
responses in all volunteers from 8 weeks postinfection. At 12 
weeks, 4 additional antigens (61, 62, 83, and 106), which were 
already positive in 2 of 3 individuals at 8 weeks, were detected 
in all participants (Figure  3). It is remarkable that 5 of the 9 
antigens seropositive by week 12 contained a saposin domain 
(proteins 44, 61, 62, 63, and 65), whereas proteins 67, 68, and 
83 all belong to the cathepsin family of proteases. The number 
of antigens seropositive in all individuals increased over time 
up to week 20, so, in total, 20 antigens were immunoreactive in 
all volunteers for at least 1 time point, whereas another 17 were 
observed in at least 2 participants.
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Figure 2. The majority of recombinant proteins are immunoreactive to sera from individuals living in schistosomiasis-endemic areas and contain heat-labile conformational 
epitopes. Recombinant proteins were probed with pooled sera from individuals living in schistosomiasis-endemic areas (“infected,” red checked bars) or individuals from the 
United Kingdom who have never been infected (“control,” green dotted bars). To test for the presence of heat-labile epitopes, recombinant proteins were also heat-treated 
(80°C, 10 minutes) before being exposed to immune sera (“infected heat treated,” orange hatched bars). All except 2 proteins (18 and 57, shown in blue) were seropositive, 
as determined by A
protein
 > A
control
 + 3SD
control
 ( = 0.201) (red dashed line), where control is the rat Cd4d3 + 4 protein tag. High immunoreactivity was determined as A
protein
 > 0.3 
(green dotted line). Proteins that exhibited little or no loss of reactivity after heat treatment are shown in italics, including 16 highly reactive proteins (6, 7, 14, 16, 19, 30, 32, 
34, 36, 42, 49, 54, 56, 89, 101, 105). All measurements were performed in triplicate; error bars = standard deviation.
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Early diagnosis of infection before the onset of symptoms 
would be very valuable; therefore, we analyzed weekly sam-
ples from all 3 individuals until week 8 against the 9 antigens 
positive in all volunteers at the 12-week time point (Figure 4). 
Immunoreactivity was observed in all volunteers as early as 5 
weeks postinfection for proteins 44 and 65, 6 weeks for pro-
tein 68, and 7 weeks for proteins 63 and 67. As observed pre-
viously, only 2 of the 3 participants were reactive to proteins 
61, 62, 83, and 106 between 5 and 8 weeks postinfection. In 
the case of antigens 44, 65, 68, and 106, seropositivity in-
creased sharply between weeks 4 and 6 before plateauing at 
later time points.
To further determine the sensitivity of detection, we quan-
tiied the immunoreactivity in 3 volunteers exposed to only 10 
cercariae (Figure 5). At 4 weeks, only 1 individual (participant 
E) was weakly seropositive for protein 44. All 3 volunteers were 
seropositive for proteins 44 and 65 at 8 weeks and reacted to 
all other antigens, except protein 83 by 12 weeks. Although 
immunoreactivity was lower than with the 30-cercariae dose 
and interindividual variability was present, proteins 44 and 
65 were again the most immunogenic antigens. In conclusion, 
individuals experimentally infected with small numbers of S 
mansoni cercariae showed seropositivity to 5 antigens as early 
as 5 to 7 weeks postinfection. 
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Figure 3. Identiication of early markers of infection in human volunteers experimentally infected with Schistosoma mansoni male cercariae. Three individuals were each 
infected with 30 male cercariae, and their antibody response to 103 Schistosoma antigens were monitored every 4 weeks over a period of 20 weeks. The number of positive 
antigens increased over time with the most highly immunoreactive antigens containing saposin domains (proteins 44, 61, 62, 63, and 65) or belonging to the cathepsin family 
of proteases (proteins 67, 68, and 83). Colored symbols represent time point readings for each individual. Data points represent mean ± standard deviation; n = 3.
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Figure 4. Kinetics of human antibody response to early markers of infection using sera from experimental infections by Schistosoma mansoni. Immunoreactivity to S 
mansoni antigens were quantiied on a weekly basis in 3 individuals infected with 30 male cercariae. Reactivity to proteins 44 and 65 could be detected in all volunteers as 
early as 5 weeks postinfection. The control antigen corresponds to the rat Cd4d3 + 4 protein tag. Data points represent mean ± standard deviation; n = 3.
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The Humoral Response Elicited by Mixed-Sex Infections in Mice Is 
Broadly Similar to That of Humans
Although sera from experimental infections with male carcariae 
identified valuable diagnostic antigens, any female-restricted 
antigens would not have been identified. To address this in a 
controlled experimental setting, we used mice as an animal 
model of infection. Sera were collected from mice infected either 
percutaneously with 200 cercariae or through intraperitoneal 
injection of 350 cercariae, and their serological responses were 
quantified (Figure 6). None of the antigens showed consistent 
reactivity across samples at 8 days postinfection, as expected; 
however, reactivity to antigen 44, and to a lesser extent, antigen 
3, could be detected across all samples from day 21. At 42 days, 
an additional 8 antigens showed reactivity across all sera tested. 
Overall, reactivity with the pool of sera from mice infected 
intraperitoneally was stronger than individual mice infected 
percutaneously, possibly due to the higher number of cercariae 
used. Just like in human samples, proteins 44, 62, 63, 67, 68, 
and 106 were the most immunoreactive. In addition, reactivity 
to the Ly6 family members Ly6F, Ly6B, and Ly6D (proteins 3, 
10, and 41, respectively) was detected at an earlier time point 
in mice than it was in humans. It is interesting to note that pro-
teins 61 and 65, which were positive between 5 and 6 weeks 
postinfection in humans, did not react with murine samples, 
whereas conversely protein 71 generated a stronger response 
in mice.
DISCUSSION
Despite its widespread distribution and high morbidity rate, 
schistosomiasis remains a neglected tropical disease whose 
true incidence and health impact remains underestimated [6]. 
In this study, we have described a recombinant protein library 
containing secreted and cell-surface proteins from different 
developmental stages of S mansoni, and together with sera 
obtained from a recently established controlled human infec-
tion model [33] we used it to determine the kinetics of the hu-
moral response to S mansoni infection. Although other large 
arrays of parasite proteins have been used for diagnostic and 
immuno-epidemiological purposes, they have mostly relied on 
cell-free or bacterial expression systems [35, 36]. Mammalian 
expression systems are more suitable for the addition of struc-
turally important posttranslational modifications found on 
extracellular proteins and thereby preserve conformational 
epitopes that can be recognized by antibodies. Using this ap-
proach, we successfully expressed 103 proteins, the majority of 
which were observed at their expected size. Although the 12 
proteins we could not express were equally distributed among 
the different protein families represented in the library, 3 of 
them corresponded to elastases. Using pooled plasma from 
patients living in a high-transmission region of Uganda, we 
observed that 64% of the expressed proteins were strongly 
immunoreactive (A
280 
> 0.3) with the majority (82%) showing 
sensitivity to heat treatment, an indicator of tertiary folding. 
Although the lower immunoreactivity for 37 proteins may sug-
gest incorrect folding, they could also be weakly immunogenic 
in humans or not directly exposed to the host immune system. 
Of the 16 most immunoreactive proteins observed, 11 had al-
ready been identified in the surface and secreted proteome of S 
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Figure 5. Early reactivity to Schistosoma mansoni antigens is detectable in in-
dividuals challenged with just 10 cercariae. The immune response from 3 human 
volunteers infected with 10 male S mansoni cercariae was monitored at 4, 8, and 
12 weeks postinfection. Reactivity to antigens 44 and 65 was detected in all parti-
cipants at 8 weeks and as early as 4 weeks in the case of participant E and antigen 
44. With the exception of protein 83, all volunteers were immunoreactive for the 
antigens tested at 12 weeks postinfection. Data points represent mean ± standard 
deviation; n = 3.
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mansoni; by contrast, only 6 of the 37 proteins with low serum 
reactivity (16%) have already been described in proteomics 
studies. The use of a single mammalian expression system for 
the production of large panels of proteins is particularly attrac-
tive for the systematic comparison of antigens in diagnostic, 
immuno-epidemiological, or vaccination studies, and we have 
used this approach previously to identify potentially protective 
antibodies against malaria [24, 25, 30].
Mass administration of praziquantel to schoolchildren has 
been the mainstay of control programs against schistosomiasis, 
and this has proved relatively successful in reducing parasite 
burdens and contributing to elimination from some areas [37]. 
Continued surveillance and early detection of new cases re-
mains critical to avoid any risk of resurgence; however, the com-
monly used Kato-Katz method is not sensitive enough to detect 
low levels of parasitemia, resulting in the underestimation of the 
real number of cases [7]. Detection of parasite-derived glycans 
such as CAA in the urine or serum of patients by lateral-low 
test is currently considered the most sensitive assay for the de-
tection of current Schistosoma infections because it can detect 
very low infection levels and reactivity disappears rapidly ater 
praziquantel treatment [8, 38]. In areas where schistosomi-
asis has been eliminated or is close to elimination, alternative 
methods of surveillance might be needed. By persisting several 
months or even years ater infection [39], antibody responses 
provide a useful historical measure of parasite exposure to 
monitor populations at risk of resurgence. Currently, most host 
antibody responses are measured against crude parasite pre-
parations such SEA or SWAP, which may sufer from consider-
able cross-reactivity with other helminths antigens. herefore, 
species-speciic recombinant proteins as diagnostic tools could 
be more reliable.
A striking feature of this study is the relatively small number 
of antigens eliciting a patent immune response in the few weeks 
ater a primary infection. In humans, almost no IgM/IgG re-
sponse could be detected before 4 to 5 weeks postinfection: 
some antigens might be more highly expressed at later stages of 
parasite development, or the parasite could evade the host im-
mune response. Subsequently, antibody responses were almost 
exclusively directed at secreted proteins belonging to the saposin 
and cathepsin families. Of the 9 proteins reactive in all human 
volunteers before 12 weeks, 5 contained saposin domains and 
3 were cathepsins. It is interesting to note that several saposin 
domain-containing proteins from Schistosoma japonicum 
have been proposed as markers of infections in mice and hu-
mans [40–42], whereas proteins 66 and 67, 2 isoforms of the 
cathepsin B1 protease, seem to have built-in adjuvanticity [43]. 
Both saposins and cathepsins are produced by the schistosome’s 
alimentary tract and have been involved in the digestion of 
lipids and proteins [44, 45]. heir reactivity to the host humoral 
system suggests they are produced by the parasite at an early 
stage. Although 5 of the 6 saposin-domain-containing proteins 
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Figure 6. Analysis of the acquired antibody response to Schistosoma mansoni antigens in experimentally infected mice. Individual sera from 3 mice infected percutane-
ously (PC) or pooled sera from 3 mice infected intraperitoneally (IP) were analyzed at 8, 21, and 42 days postinfection. The aim was to try and capture the antibody reactivity 
at different stages of parasite maturation: schistosomule at 8 days, immature adult at 21 days, and mature adult at 42 days. Proteins 44 and 3 were immunopositive at 
day 21, and 8 additional proteins (10, 41, 62, 63, 64, 67, 68, 106) were immunopositive at day 42. Each data point represents the average of triplicate experiments; error 
bars = standard deviation.
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present in the library were immunoreactive (although reactivity 
of protein 83 remained modest up to 12 weeks), they share only 
9% to 28% sequence identity, making cross-reactivity unlikely. 
he dynamics of the host response to the recombinant saposins 
closely parallels the detection of the parasite CAA glycans in the 
sera of infected patients, which is irst detected at 4 weeks [38].
Reactivity to members of the uPAR/Ly6 domain-containing 
family, which are expressed at the somule and adult stages [46–
48], was also consistently observed across human and murine 
samples. In our study, reactivity to Ly6F, Ly6B, and Ly6D (pro-
teins 3, 10, and 41, respectively) was observed in both human 
and mouse serum samples, whereas reactivity to Ly6A and Ly6I 
(proteins 11 and 2, respectively) was only detected in human 
samples. hree of these proteins (Ly6B, Ly6D, and Ly6F) have 
been shown to elicit strong antibody responses in rat, mouse, 
and human sera [48]. Although they share some homology with 
the complement-inactivating Cd59 protein, they do not seem to 
have conserved the same function [46].
CONCLUSIONS
By producing recombinant proteins in a mammalian expres-
sion system, we have paid particular attention to their correct 
folding, and thus this new resource could be used in a wide 
range of cellular and molecular assays such as vaccine screening 
[49], cellular assays looking at immunomodulatory functions, 
immunoepidemiological studies, or the identification of host 
binding partners by receptor-ligand screening. We envisage 
these proteins will be useful to the wider scientific community 
to further understand Schistosoma biology.
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